Supplementary material: Controlled release of bupivacaine using hybrid thermoresponsive nanoparticles activated via photothermal heating
Fig. S1. Cell cycle population distribution (percentage of cells, %) after treatment with HGNPs@P(MEO2MA-co-OEGMA500) nanoparticles (NPs) for 24 h. Table S1. Percentages of both early and late apoptotic, alive and necrotic cells after treatment with HGNPs@P(MEO2MA-co-OEGMA500) nanoparticles (NPs) fo...
| Autores: | , , , , |
|---|---|
| Tipo de recurso: | conjunto de datos |
| Fecha de publicación: | 2018 |
| País: | España |
| Institución: | Consejo Superior de Investigaciones Científicas (CSIC) |
| Repositorio: | DIGITAL.CSIC. Repositorio Institucional del CSIC |
| OAI Identifier: | oai:digital.csic.es:10261/366722 |
| Acceso en línea: | http://hdl.handle.net/10261/366722 |
| Access Level: | acceso abierto |
| Sumario: | Fig. S1. Cell cycle population distribution (percentage of cells, %) after treatment with HGNPs@P(MEO2MA-co-OEGMA500) nanoparticles (NPs) for 24 h. Table S1. Percentages of both early and late apoptotic, alive and necrotic cells after treatment with HGNPs@P(MEO2MA-co-OEGMA500) nanoparticles (NPs) for 24 h. |
|---|